{"id":9233,"date":"2026-02-23T18:25:32","date_gmt":"2026-02-23T18:25:32","guid":{"rendered":"https:\/\/stoxpo.com\/?p=9233"},"modified":"2026-02-23T18:25:32","modified_gmt":"2026-02-23T18:25:32","slug":"vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/","title":{"rendered":"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>Regulatory green light strengthens commercial outlook and expands product portfolio<\/em><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Shares of Vanda Pharmaceuticals (VNDA) moved higher after the company announced that the U.S. Food and Drug Administration (FDA) has approved its BYSANTI tablets. The regulatory milestone marks an important achievement for the biopharmaceutical company and provides investors with renewed confidence in its product pipeline and growth prospects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s approval clears the way for Vanda to begin commercialization of BYSANTI in the United States, adding a new product to its portfolio. Regulatory approvals are often pivotal moments for pharmaceutical companies, as they transition a therapy from development into revenue generation. The approval not only validates the clinical data supporting the drug but also signals that the treatment has met the agency\u2019s standards for safety and efficacy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investors responded positively to the news, driving the stock higher in trading. For emerging and mid-sized pharmaceutical companies, FDA approvals can significantly improve financial visibility by opening the door to new revenue streams and potential market share gains. In addition, such milestones can enhance strategic positioning, particularly if the therapy addresses an unmet medical need or enters a market with favorable demand dynamics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The approval of BYSANTI also strengthens Vanda\u2019s broader growth strategy. Expanding its portfolio reduces reliance on existing products and diversifies revenue potential. Successful product launches can further support long-term research and development initiatives, allowing the company to reinvest in innovation and pipeline expansion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While commercialization efforts will be closely watched in the coming quarters, the FDA decision represents a clear positive catalyst for Vanda. With regulatory approval secured, the company now shifts focus to launch execution, physician adoption, and patient access.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Overall, the approval of BYSANTI tablets reinforces Vanda Pharmaceuticals\u2019 commitment to advancing new therapies and positions the company for potential revenue growth as it moves into its next phase of development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/gilead-sciences-to-acquire-arcellx-sending-shares-higher\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Gilead Sciences to Acquire Arcellx, Sending Shares Higher<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regulatory green light strengthens commercial outlook and expands product portfolio Shares of Vanda Pharmaceuticals (VNDA) moved higher after the company announced that the U.S. Food and Drug Administration (FDA) has approved its BYSANTI tablets. The regulatory milestone marks an important achievement for the biopharmaceutical company and provides investors with renewed confidence in its product pipeline [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1142,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,361],"tags":[451,421,416,418,417,880],"coauthors":[453],"class_list":["post-9233","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-large-cap","tag-fda","tag-growth","tag-movers","tag-news","tag-stock-market","tag-vnda"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Regulatory green light strengthens commercial outlook and expands product portfolio Shares of Vanda Pharmaceuticals (VNDA) moved higher after the company announced that the U.S. Food and Drug Administration (FDA) has approved its BYSANTI tablets. The regulatory milestone marks an important achievement for the biopharmaceutical company and provides investors with renewed confidence in its product pipeline [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-23T18:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI\",\"datePublished\":\"2026-02-23T18:25:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/\"},\"wordCount\":327,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"keywords\":[\"FDA\",\"Growth\",\"Movers\",\"News\",\"Stock Market\",\"VNDA\"],\"articleSection\":[\"Biotechnology\",\"Large-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/\",\"name\":\"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"datePublished\":\"2026-02-23T18:25:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/02\\\/23\\\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/","og_locale":"en_US","og_type":"article","og_title":"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI - Stoxpo","og_description":"Regulatory green light strengthens commercial outlook and expands product portfolio Shares of Vanda Pharmaceuticals (VNDA) moved higher after the company announced that the U.S. Food and Drug Administration (FDA) has approved its BYSANTI tablets. The regulatory milestone marks an important achievement for the biopharmaceutical company and provides investors with renewed confidence in its product pipeline [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/","og_site_name":"Stoxpo","article_published_time":"2026-02-23T18:25:32+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI","datePublished":"2026-02-23T18:25:32+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/"},"wordCount":327,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","keywords":["FDA","Growth","Movers","News","Stock Market","VNDA"],"articleSection":["Biotechnology","Large-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/","url":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/","name":"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","datePublished":"2026-02-23T18:25:32+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2026\/02\/23\/vanda-pharmaceuticals-gains-on-fda-approval-of-bysanti\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Vanda Pharmaceuticals Gains on FDA Approval of BYSANTI"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=9233"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9233\/revisions"}],"predecessor-version":[{"id":9234,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9233\/revisions\/9234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1142"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=9233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=9233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=9233"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=9233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}